Tag: Cereblon E3 ligase modulator

Tag Visualization: Top 50 related tags by occurrence

Recent Related Articles to Cereblon E3 ligase modulator

FDA Approves Isatuximab With Bortezomib, Lenalidomide, and Dexamethasone for NDMM

Added to Collection on: 2024-09-20 22:20:25

Tags for this article:

Orphan drugs
Isatuximab
Multiple myeloma
Lenalidomide
Bortezomib
Cereblon E3 ligase modulator
Dexamethasone
Progression-free survival
Selinexor
Daratumumab/hyaluronidase

Click the tags to see associated articles and topics

View Article Details
Lenalidomide-Obinutuzumab Combo Yields Promising Results in Relapsed NHL

Added to Collection on: 2024-09-21 20:27:49

Tags for this article:

Orphan drugs
Lenalidomide
Obinutuzumab
Rituximab
Cereblon E3 ligase modulator
Indolent lymphoma
Lymphoma
Hodgkin lymphoma
Chronic lymphocytic leukemia
Carfilzomib
Selinexor

Click the tags to see associated articles and topics

View Article Details
Isatuximab/VRd Elicits Sustained MRD Rates in Newly Diagnosed Myeloma - OncLive

Added to Collection on: 2024-12-10 00:08:02

Tags for this article:

Orphan drugs
Isatuximab
Multiple myeloma
Minimal residual disease
Lenalidomide
Bortezomib
Dexamethasone
Cereblon E3 ligase modulator
CD38
Robert Z. Orlowski

Click the tags to see associated articles and topics

View Article Details
How Anti–CD-38 Antibodies Are Changing the Standard of Myeloma Care

Added to Collection on: 2024-12-10 19:49:13

Tags for this article:

Orphan drugs
Immune system
Immunology
Cancer treatments
Multiple myeloma
Monoclonal antibody
CAR T cell
Bispecific monoclonal antibody
Cereblon E3 ligase modulator
B-cell maturation antigen
Talquetamab
CD38
the university of texas md anderson cancer center

Click the tags to see associated articles and topics

View Article Details
China's NMPA Approves Isatuximab Plus VRd for Newly Diagnosed, Transplant-Ineligible Myeloma

Added to Collection on: 2025-01-31 22:36:35

Tags for this article:

Orphan drugs
Immunosuppressants
Antineoplastic drugs
Pyrazines
Teratogens
Isatuximab
Multiple myeloma
Lenalidomide
Bortezomib
Progression-free survival
VRD
Cereblon E3 ligase modulator
Dexamethasone

Click the tags to see associated articles and topics

View Article Details
Key Trials From ASH 2024 Impact Treatment for Plasma Cell Disorders Going Forward

Added to Collection on: 2025-02-20 14:05:40

Tags for this article:

Orphan drugs
Multiple myeloma
Isatuximab
Daratumumab
Smouldering myeloma
Lenalidomide
Bortezomib
Cereblon E3 ligase modulator
B-cell maturation antigen
Proteasome inhibitor
Dexamethasone
Monoclonal gammopathy of undetermined significance

Click the tags to see associated articles and topics

View Article Details
MRD Monitoring May Help Redefine Long-Term Goals in Myeloma Therapy

Added to Collection on: 2025-06-01 23:28:31

Tags for this article:

Immunosuppressants
Oncology
Leukemia
Minimal residual disease
Orphan drugs
Multiple myeloma
Lenalidomide
Carfilzomib
MRD
Celgene
Cereblon E3 ligase modulator
Cancer treatment

Click the tags to see associated articles and topics

View Article Details
Multiple Myeloma Market Size to Reach USD 46.94 Billion by 2032 - GlobeNewswire

Added to Collection on: 2025-08-08 16:31:08

Tags for this article:

Orphan drugs
Immunosuppressants
Antineoplastic drugs
Aromatic amines
Phthalimides
Multiple myeloma
Isatuximab
Daratumumab
Lenalidomide
Cereblon E3 ligase modulator
Carfilzomib
Targeted therapy

Click the tags to see associated articles and topics

View Article Details
Elranatamab Plus Daratumumab and Lenalidomide Yields Durable Responses, Manageable Safety

Added to Collection on: 2025-09-18 23:02:21

Tags for this article:

Orphan drugs
Daratumumab
Multiple myeloma
Lenalidomide
Cereblon E3 ligase modulator
CD38
Celgene
Proteasome inhibitor
Cevostamab
Isatuximab
Celgene Corporation
Pfizer
Canada
Toronto
Janssen Biotech Inc.

Click the tags to see associated articles and topics

View Article Details
Five Under 5: Top Oncology Videos for the Week of 10/5 | OncLive

Added to Collection on: 2025-10-12 14:18:01

Tags for this article:

Orphan drugs
Primary myelofibrosis
Ruxolitinib
Ixazomib
Pembrolizumab
Cereblon E3 ligase modulator
Multiple myeloma
Triple-negative breast cancer
Janus kinase inhibitor
Temozolomide
Lenalidomide
Olaparib

Click the tags to see associated articles and topics

View Article Details
Book a Demo